drugset / Trial / NCT07177872

A Long-term Efficacy and Safety of NTQ5082 Capsules

NCT07177872

Phase 3 Not yet recruiting 78 enrolled Nanjing Chia-tai Tianqing Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

NTQ5082 capsules are a small molecule CFB inhibitor. This study is a multicenter, open-label study evaluating the long-term efficacy and safety of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria

Timeline

Start
2026-06
Primary completion
2028-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject NTQ5082 Small molecule 200 mg